AstraZeneca enters big pharma deals with Par Pharmaceutical Companies for an exclusive U.S. supply and distribution agreement in which Par will distribute the authorized generic version of AstraZeneca's Atacand.
As part of the pharma deals, Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets.
According to IMS Health data, annual U.S. sales of Atacand are approximately $113 million.
Candesartan cilexetil is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults and children 1 to < 17 years of age and the treatment of congestive heart failure.
Candesartan cilexetil reduces cardiovascular death and heart failure hospitalization.
Par Pharmaceutical Companies is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.
Daily news stories
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with AstraZeneca
Report: Congestive Heart Failure Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity